Immunocellular Therapeutics (IMUC) Sees Significant Decrease in Short Interest

Immunocellular Therapeutics (NYSEAMERICAN:IMUC) was the target of a significant drop in short interest during the month of May. As of May 15th, there was short interest totalling 3,133,932 shares, a drop of 4.5% from the April 30th total of 3,281,161 shares. Based on an average trading volume of 559,678 shares, the short-interest ratio is presently 5.6 days. Approximately 7.5% of the shares of the stock are sold short.

IMUC opened at $0.27 on Friday. Immunocellular Therapeutics has a 52 week low of $0.03 and a 52 week high of $2.79.

Immunocellular Therapeutics (NYSEAMERICAN:IMUC) last posted its quarterly earnings data on Monday, May 14th. The biotechnology company reported ($0.02) EPS for the quarter.

About Immunocellular Therapeutics

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers. Its products include ICT-107, a dendritic cell (DC) immunotherapy for the treatment of diagnosed glioblastoma multiforme (GBM); ICT-140, a DC-based immunotherapy targets tumor associated antigens on ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs to treat recurrent GBM and other solid tumor cancers.

Receive News & Ratings for Immunocellular Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocellular Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply